100% increase in Patient Access to Biologic Treatments thanks to Biosimilar Medicines

30 March 2016

Biosimilar medicines represent an essential opportunity to optimise patient access to […]

EGA becomes Medicines for Europe

10 March 2016

The European Generic and Biosimilar Medicines Association is now Medicines […]

IGBA calls for full transparency and new timelines for impact assessment with regard to the voluntary WHO biological qualifier (BQ) proposal

2 March 2016

Medicines for Europe: Better Access, Better Health

1 March 2016

EGA Prioritises Pursuing Sustainability Agreements

12 February 2016

The European Biosimilars Group Appoints New Leadership Team With Sandoz’ Carol Lynch and Polpharma’s Klaus Martin

10 February 2016

Last week in Brussels, the European Biosimilar medicines Group (EBG […]

EGA Welcomes the Delegated Regulation as a Tool To Fight Counterfait Medicines

9 February 2016

Brussels – The European Generic and Biosimilar Medicines Association (EGA) welcomes […]

Shaping The 2020 Regulatory Landscape For Patient Needs

28 January 2016

London – 61 regulators from 25 countries made progress in improving the […]

Industry Coming Together To Improve Safety For Patients

26 January 2016

London – In London this week, the European Generic and Biosimilar medicines […]

Piden fabricar genéricos en periodo de extensión

25 January 2016

El presidente de la EGA considera que actualmente la industria […]